|
 |
| home > ebr > spring 2002 > pharmacogenetics and the development of anticancer agents |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| The observation that individuals respond differently to the same drug is centuries old, yet only recently has the biological basis for such variation begun to be unravelled. In the field of pharmacogenetics, detailed biological understanding of the pathways by which drugs act and are metabolised, guides high throughput DNA sequencing efforts to reveal variations within genes critical to therapeutic response. Such variance data is used to associate responsiveness to a drug with specific genetic variations, which can then serve as predictive markers to guide drug usage. This article summarises progress in identifying genetic markers that predict the toxicity and efficacy of chemotherapeutic drugs. Several types of markers have been associated with response to a variety of anticancer agents, including DNA polymorphisms, loss of heterozygosity, and RNA expression patterns within tumours. Some genetic features of cancer that provide the basis for these markers are outlined briefly, examples of each type of marker are provided, and the utility of pharmacogenetics throughout the drug development process is discussed. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Inaugural Conference on Pre-Filled Syringes
21-22 January 2009, Crowne Plaza Hotel - St James, London, UK
SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
